Get started
Vincerx Pharma, Inc.Vincerx Pharma, Inc.Vincerx Pharma, Inc.

Vincerx Pharma, Inc.

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals

VINC chart


Full chart

Key facts today

Vincerx Pharma is merging with Oqory, Inc., with Oqory investors holding 95% of the new entity. Vincerx shares surged in after-hours trading following the announcement.
Analyze the impactAnalyze the impact

VINC upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪6.53 M‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−1.0309 USD
Net income (FY)
‪−40.16 M‬ USD
Revenue (FY)
0.00 USD
Shares float
‪25.70 M‬
Beta (1Y)
2.13

Employees


Employees (FY)
42
Change (1Y)
+1 +2.44%
Revenue / Employee (1Y)
0.00 USD
Net income / Employee (1Y)
‪−956.12 K‬ USD

About Vincerx Pharma, Inc.


Sector
Health Technology
CEO
Ahmed M. Hamdy
Headquarters
Palo Alto
Website
vincerx.com
Founded
2018
FIGI
BBG00RRQXMX2
Vincerx Pharma, Inc. operates as a clinical-stage biopharmaceutical company which develops antibody drugs. It focuses on leveraging its extensive development and oncology expertise to advance new therapies intended to address unmet medical needs for the treatment of cancer. The firm pipeline is derived from a license agreement with Bayer and includes: a clinical-stage and follow-on small molecule drug program and preclinical stage bioconjugation/next-generation antibody-drug conjugate platform. The company was founded by Ahmed M. Hamdy, Raquel E. Izumi, Tom C. Thomas, Soo In Hwang and John C. Byrd on December 19, 2018 and is headquartered in Palo Alto, CA.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

VINC news



Ideas



See all ideas 

Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of VINC is 0.3705 USD — it has increased by 5.49% in the past 24 hours. Watch Vincerx Pharma, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Vincerx Pharma, Inc. stocks are traded under the ticker VINC.
VINC stock has risen by 4.86% compared to the previous week, the month change is a −24.60% fall, over the last year Vincerx Pharma, Inc. has showed a −63.68% decrease.
We've gathered analysts' opinions on Vincerx Pharma, Inc. future price: according to them, VINC price has a max estimate of 10.00 USD and a min estimate of 2.00 USD. Watch VINC chart and read a more detailed Vincerx Pharma, Inc. stock forecast: see what analysts think of Vincerx Pharma, Inc. and suggest that you do with its stocks.
VINC reached its all-time high on Mar 18, 2021 with the price of 26.7500 USD, and its all-time low was 0.1754 USD and was reached on Dec 26, 2024. View more price dynamics on VINC chart.
See other stocks reaching their highest and lowest prices.
VINC stock is 113.61% volatile and has beta coefficient of 2.13. Track Vincerx Pharma, Inc. stock price on the chart and check out the list of the most volatile stocks — is Vincerx Pharma, Inc. there?
Today Vincerx Pharma, Inc. has the market capitalization of ‪6.53 M‬, it has decreased by −13.79% over the last week.
Yes, you can track Vincerx Pharma, Inc. financials in yearly and quarterly reports right on TradingView.
Vincerx Pharma, Inc. is going to release the next earnings report on Apr 1, 2025. Keep track of upcoming events with our Earnings Calendar.
VINC earnings for the last quarter are −0.17 USD per share, whereas the estimation was −0.22 USD resulting in a 21.54% surprise. The estimated earnings for the next quarter are −0.15 USD per share. See more details about Vincerx Pharma, Inc. earnings.
Vincerx Pharma, Inc. revenue for the last quarter amounts to 0.00 USD, matching the estimated figure, and no changes in revenue are expected for the next quarter.
VINC net income for the last quarter is ‪−7.84 M‬ USD, while the quarter before that showed ‪−1.81 M‬ USD of net income which accounts for −333.79% change. Track more Vincerx Pharma, Inc. financial stats to get the full picture.
No, VINC doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Dec 30, 2024, the company has 42.00 employees. See our rating of the largest employees — is Vincerx Pharma, Inc. on this list?
Like other stocks, VINC shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Vincerx Pharma, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Vincerx Pharma, Inc. technincal analysis shows the buy rating today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Vincerx Pharma, Inc. stock shows the sell signal. See more of Vincerx Pharma, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.